Friday, October 28, 2016

Dexametasona Indukern




Dexametasona Indukern may be available in the countries listed below.


Ingredient matches for Dexametasona Indukern



Dexamethasone

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Dexametasona Indukern in the following countries:


  • Spain

International Drug Name Search


Ovispec




Ovispec may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Ovispec



Albendazole

Albendazole is reported as an ingredient of Ovispec in the following countries:


  • United Kingdom

International Drug Name Search


Vitole E




Vitole E may be available in the countries listed below.


Ingredient matches for Vitole E



Tocopherol, α-

Tocopherol, α- is reported as an ingredient of Vitole E in the following countries:


  • Poland

International Drug Name Search


Dobupum




Dobupum may be available in the countries listed below.


Ingredient matches for Dobupum



Dobutamine

Dobutamine is reported as an ingredient of Dobupum in the following countries:


  • Japan

International Drug Name Search


Salamol




Salamol may be available in the countries listed below.


Ingredient matches for Salamol



Salbutamol

Salbutamol is reported as an ingredient of Salamol in the following countries:


  • Georgia

  • Romania

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Salamol in the following countries:


  • Denmark

  • Malta

  • New Zealand

  • Switzerland

  • United Kingdom

International Drug Name Search


Sterapred




In the US, Sterapred (prednisone systemic) is a member of the drug class glucocorticoids and is used to treat Acute Lymphocytic Leukemia, Adrenocortical Insufficiency, Adrenogenital Syndrome, Allergic Reactions, Ankylosing Spondylitis, Aspiration Pneumonia, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Bullous Pemphigoid, Bursitis, Chorioretinitis, Cluster Headaches, Cogan's Syndrome, Conjunctivitis - Allergic, Corneal Ulcer, Dermatitis Herpetiformis, Dermatomyositis, Eczema, Epicondylitis - Tennis Elbow, Erythroblastopenia, Fibromyalgia, Gouty Arthritis, Graft-versus-host disease, Hay Fever, Herpes Zoster, Herpes Zoster Iridocyclitis, Hypercalcemia of Malignancy, Idiopathic Thrombocytopenic Purpura, Immunosuppression, Inflammatory Conditions, Iridocyclitis, Iritis, Juvenile Rheumatoid Arthritis, Keratitis, Leukemia, Lichen Planus, Lichen Sclerosus, Loeffler's Syndrome, Lymphoma, Multiple Sclerosis, Mycosis Fungoides, Nephrotic Syndrome, Neurosarcoidosis, Osteoarthritis, Pemphigoid, Pemphigus, Pharyngitis, Polymyositis/Dermatomyositis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sarcoidosis, Seborrheic Dermatitis, Sinusitis, Skin Rash, Synovitis, Systemic Lupus Erythematosus, Systemic Sclerosis, Thrombocytopenia, Toxic Epidermal Necrolysis, Tuberculosis - Extrapulmonary, Tuberculous Meningitis, Ulcerative Colitis and Uveitis - Posterior.

US matches:

  • Sterapred

  • Sterapred DS

Ingredient matches for Sterapred



Prednisone

Prednisone is reported as an ingredient of Sterapred in the following countries:


  • United States

International Drug Name Search


Agrylin


Agrylin is a brand name of anagrelide, approved by the FDA in the following formulation(s):


AGRYLIN (anagrelide hydrochloride - capsule; oral)



  • Manufacturer: SHIRE LLC

    Approval date: March 14, 1997

    Strength(s): EQ 0.5MG BASE [AB]

Has a generic version of Agrylin been approved?


Yes. The following products are equivalent to Agrylin:


anagrelide hydrochloride capsule; oral



  • Manufacturer: ALPHAPHARM

    Approval date: June 27, 2006

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: BARR

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: IMPAX LABS

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: IVAX SUB TEVA PHARMS

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: SANDOZ

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: WATSON LABS

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Agrylin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Agrylin.

See also...

  • Agrylin Consumer Information (Wolters Kluwer)
  • Agrylin Consumer Information (Cerner Multum)
  • Agrylin Advanced Consumer Information (Micromedex)
  • Agrylin AHFS DI Monographs (ASHP)
  • Anagrelide Consumer Information (Wolters Kluwer)
  • Anagrelide Consumer Information (Cerner Multum)
  • Anagrelide Advanced Consumer Information (Micromedex)
  • Anagrelide hydrochloride AHFS DI Monographs (ASHP)